These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585 [TBL] [Abstract][Full Text] [Related]
25. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction. Russell S Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796 [TBL] [Abstract][Full Text] [Related]
26. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Davidson MH Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792 [TBL] [Abstract][Full Text] [Related]
27. Incretins and preservation of endothelial function. Koska J Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):295-308. PubMed ID: 22827294 [TBL] [Abstract][Full Text] [Related]
28. Incretins and microRNAs: Interactions and physiological relevance. Radbakhsh S; Sathyapalan T; Banach M; Sahebkar A Pharmacol Res; 2020 Mar; 153():104662. PubMed ID: 31982487 [TBL] [Abstract][Full Text] [Related]
29. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Boland CL; Degeeter M; Nuzum DS; Tzefos M Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652 [TBL] [Abstract][Full Text] [Related]
30. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Neumiller JJ J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361 [TBL] [Abstract][Full Text] [Related]
32. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047 [TBL] [Abstract][Full Text] [Related]
33. Use of incretin-based therapy in hospitalized patients with hyperglycemia. Umpierrez GE; Schwartz S Endocr Pract; 2014 Sep; 20(9):933-44. PubMed ID: 25100362 [TBL] [Abstract][Full Text] [Related]
34. The incretin system and its role in type 2 diabetes mellitus. Holst JJ; Vilsbøll T; Deacon CF Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605 [TBL] [Abstract][Full Text] [Related]
35. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond. João AL; Reis F; Fernandes R Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902 [TBL] [Abstract][Full Text] [Related]
36. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Davies M; Speight J Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869 [TBL] [Abstract][Full Text] [Related]
37. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. Cornell S J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069 [TBL] [Abstract][Full Text] [Related]
38. [Drugs affecting the incretin system and renal glucose transport: do they meet the expectations of modern therapy of type 2 diabetes?]. Gumieniczek A Postepy Hig Med Dosw (Online); 2016 May; 70():425-34. PubMed ID: 27180961 [TBL] [Abstract][Full Text] [Related]
39. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure. Takahashi A; Ihara M; Yamazaki S; Asanuma H; Asakura M; Kitakaze M Int Heart J; 2015; 56(4):372-6. PubMed ID: 26104180 [TBL] [Abstract][Full Text] [Related]